
    
      This is a multicenter study conducted at study sites in Russia and the Ukraine where various
      doses of ABI-007 (Abraxane) will be given in combination with carboplatin to patients with
      non-small cell lung cancer to determine the recommended dose and schedule for this
      combination therapy for Phase III trials. The primary objective of this study is to obtain
      preliminary information on the antitumor activity and adverse events of ABI-007 in
      combination with carboplatin.
    
  